Q linea

Q linea FCF/Debt

The Free Cash Flow to Debt Ratio of Q linea (QLINEA.ST) as of Nov 19, 2026 is -2,902.99 %. In the previous year, Free Cash Flow to Debt Ratio was -123.99 % — a change of 2,241.23% (lower).

FCF/Debt

-2,902.99 %

YoY

2,241.23%

Last updated:

Free Cash Flow to Debt Ratio of Q linea is 2025 -2,902.99 % . Free Cash Flow to Debt Ratio of Q linea was 2024 -123.99 % . It decreases by 2,241.23% lower compared to the previous year.

The Q linea FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-10,992.91 SEK
Jan 1, 2019
-25,020.03 SEK
Jan 1, 2020
-75,689.73 SEK
Jan 1, 2021
-1,463.93 SEK
Jan 1, 2022
-1,280.99 SEK
Jan 1, 2023
-1,151.83 SEK
Jan 1, 2024
-123.99 SEK
Jan 1, 2025
-2,902.99 SEK
The Q linea FCF/Debt history
YEARFCF/DebtYoY
-2,902.99 %+2,241.23%
-123.99 %-89.23%
-1,151.83 %-10.08%
-1,280.99 %-12.50%
-1,463.93 %-98.07%
-75,689.73 %+202.52%
-25,020.03 %+127.60%
-10,992.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Free Cash Flow to Debt Ratio of Q linea is -2,902.99 % in 2025.

Free Cash Flow to Debt Ratio of Q linea changed from -123.99 % to -2,902.99 %, representing a 2,241.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Q linea since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Q linea with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Q linea

All Key Metrics — Q linea